San
Francisco, 01 April , Point of Care (PoC) Molecular Diagnostics Market Analysis
By Application, (Infectious Diseases, Oncology, Hematology, Prenatal Testing,
Endocrinology), By Technology (PCR-based, Microarray-based,
Hybridization-based, Genetic Sequencing-based), By Test Location,
(Over-the-counter, Point-of-care), By End-use (Decentralized Labs, Hospitals,
Home-care, Assisted Living Facilities) And Segment Forecasts To 2024
Global point of care molecular diagnostics market is anticipated to reach USD 3.9
billion by 2024, according to a new report by Grand View Research, Inc. Ongoing
research & development to miniaturize molecular diagnostics testing that
provides enhanced near patient testing with high accuracy & lesser
turnaround times are major factors expected to reinforce the high growth potential
for POC MDx products.
Growing demand for CLIA tests
that are, by definition, portable and safe enough to be used in non-laboratory
settings such as pharmacy clinics, physician offices, and home-care settings,
is expected to drive demand in the market over the forecast period. Ongoing
research and development is continually supported and funded by a number of
major international entities including the national governments of developed
countries and high-value private funding agencies such as the Bill & Melinda
Gates Foundation.
Furthermore, a growing
portfolio of point-of-care testing capabilities that, had initially been
focused on screening, testing, and diagnosis of infectious diseases in
low-income developing countries, has been developing at a rapid pace over the
past decade to expand its potential market to a broader range of medical
faculties. Consequently, POC and molecular diagnosis tests are available and/or
are under development for cardiology monitoring, oncology testing, and
hematology testing.
Recent advances in the
development of microfluidics and genetic sequencing instrumentation pave the
way for development of cost-effective, highly accurate and rapid testing
platforms, which are able to be used as true POC systems. This is a key factor
that significantly contributes towards the favorably funded, high growth
potential environment prevalent in the point of care molecular diagnostics
market.
Access Full Research
Report On Point of Care (PoC) Molecular Diagnostics Market Analysis:
Further key findings from the report
suggest:
·
Application of POC MDx tests
for infectious diseases accounted for over 45% of market revenue in 2015. The
large share can be accounted for by the presence of an extensive portfolio of
the concerned tests with a number of major market entities. Furthermore,
growing disease burden of infectious diseases in developing as well as
developed countries is another factor the reinforces the dominance of this
segment.
·
PCR-based POC tests accounted
for the largest share of the market in 2015. Widespread usage of PCR-based
techniques for molecular diagnosis and commercialization of POC real time PCR
products such as the cobas LIAT by Roche have provided this segment with ample
opportunities for revenue generation and are expected to maintain a favorable
market environment over the forecast period.
·
North America was observed to
be the most lucrative region on this market and estimated to account for over
40% of the global revenue. presence of a technologically advanced medical
framework, sophisticated insurance & copayment system & high R&D
investment by governments and private funding organizations for the development
of POC MDx tests are major factors responsible for the region’s dominant market
position.
·
Key players operating in this
industry include Johnson & Johnson, Danaher Corp., Cepheid, Bio-Rad
Laboratories, bioMerieux, Becton Dickinson, Roche Diagnostics, Bayer
Healthcare, Alere Inc (Abbott), Abbott Laboratories among others.
Browse More Reports Of This Category By
Grand View Research At: https://www.grandviewresearch.com/industry/clinical-diagnostics
Grand View Research has
segmented point of care molecular diagnostics market on the basis of workflow,
mode, services, and region:
Global Point of Care Molecular
Diagnostics Application Outlook (Revenue, USD Million, 2013 - 2024)
·
Infectious Diseases
·
Oncology
·
Hematology
·
Prenatal Testing
·
Endocrinology
·
Other Applications
Global Point of Care Molecular
Diagnostics Technology Outlook (Revenue, USD Million, 2013 - 2024)
·
PCR-based
·
Genetic Sequencing-based
·
Hybridization-based
·
Microarray-based
Global Point of Care Molecular
Diagnostics Test Location Outlook (Revenue, USD Million, 2013 - 2024)
·
OTC
·
POC
Global Point of Care Molecular
Diagnostics End-use Outlook (Revenue, USD Million, 2013 - 2024)
·
Decentralized Labs
·
Hospitals
·
Home-care
·
Assisted Living Healthcare
Facilities
·
Other uses
Point of Care Molecular Diagnostics
Regional Outlook (Revenue, USD Million, 2013 - 2024)
·
North America
o U.S.
o Canada
·
Europe
o Germany
o UK
·
Asia Pacific
o China
o Japan
·
Latin America
o Brazil
·
MEA
o South Africa
Access Full
Press Release of this Report: https://www.grandviewresearch.com/press-release/global-point-of-care-poc-molecular-diagnostics-market
About Grand
View Research
Grand View Research, Inc. is a U.S. based market research
and consulting company, registered in the State of California and headquartered
in San Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To help clients make informed
business decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
For more
information: www.grandviewresearch.com/